Inter Pharma PCL (BKK:IP) Debt-to-Asset : 0.13 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Inter Pharma PCL Debt-to-Asset?

Inter Pharma PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ฿162 Mil. Inter Pharma PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ฿233 Mil. Inter Pharma PCL's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ฿3,021 Mil. Inter Pharma PCL's debt to asset for the quarter that ended in Dec. 2024 was 0.13.

Inter Pharma PCL Debt-to-Asset Historical Data

The historical data trend for Inter Pharma PCL's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inter Pharma PCL Debt-to-Asset Chart

Inter Pharma PCL Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.16

0.27

0.17

0.14

0.13

Inter Pharma PCL Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.14	0.13	0.12	0.13	0.13

Competitive Comparison of Inter Pharma PCL's Debt-to-Asset

For the Biotechnology subindustry, Inter Pharma PCL's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inter Pharma PCL's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inter Pharma PCL's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Inter Pharma PCL's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Inter Pharma PCL Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Inter Pharma PCL's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(161.727	+	232.691)	/	3020.562
	=	0.13

Inter Pharma PCL's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(161.727	+	232.691)	/	3020.562
	=	0.13

Inter Pharma PCL (BKK:IP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Inter Pharma PCL Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Inter Pharma PCL's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Inter Pharma PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inter Pharma PCL (BKK:IP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Silom Road, 140/9 ITF Tower 9th Floor, Suriyawongse, Bangrak, Bangkok, THA, 10500

Website

https://www.interpharma.co.th

Inter Pharma PCL is a biopharmaceutical company. It is engaged in the import, manufacture and distribution of drug, and dietary supplement products for humans and animals. It offers products related to Wellness and Anti-aging, Aesthetics, Diagnostics, Vitamins, and other products. The company operates in three reportable segments Human healthcare, Animal Healthcare, and Hospital and clinics in Thailand. Key revenue is derived from the Human healthcare segment.